Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Main trialPhase 1/2
- “This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.”In the company’s words, NCT05203939 on ClinicalTrials.gov
Other drugs for Retinitis Pigmentosa
- RTx-015Ray Therapeutics, Inc. · Phase 2/3
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- Voretigene neparvovec-rzylSpark Therapeutics, Inc. · Phase 3
- BS01Bionic Sight LLC · Phase 1/2
- FamzeretceljCyte, Inc · Phase 2
- SPVN06SparingVision · Phase 1/2
Coming up1
- Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Mar 2027 | Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026